Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Amakye

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Leukemia|June 11, 2011
The controversial role of the Hedgehog pathway in normal and malignant hematopoiesisB G Mar, D Amakye, I Aifantis, et al.
Clinical Pharmacology and Therapeutics|May 29, 2009
The value, qualification, and regulatory use of surrogate end points in drug developmentC D Lathia, D Amakye, W Dai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2009
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumoursD S Boss, G K Schwartz, M R Middleton, et al.
Clinical Pharmacology and Therapeutics|December 20, 2007
A prototypical process for creating evidentiary standards for biomarkers and diagnosticsC A Altar, D Amakye, D Bounos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2014
A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumorsJordi Rodon, Hussein A Tawbi, Anne L Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2014
A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastomaYaping Shou, Douglas M Robinson, Dereck D Amakye, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Leukemia|June 11, 2011
The controversial role of the Hedgehog pathway in normal and malignant hematopoiesisB G Mar, D Amakye, I Aifantis, et al.
Clinical Pharmacology and Therapeutics|May 29, 2009
The value, qualification, and regulatory use of surrogate end points in drug developmentC D Lathia, D Amakye, W Dai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2009
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumoursD S Boss, G K Schwartz, M R Middleton, et al.
Clinical Pharmacology and Therapeutics|December 20, 2007
A prototypical process for creating evidentiary standards for biomarkers and diagnosticsC A Altar, D Amakye, D Bounos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2014
A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumorsJordi Rodon, Hussein A Tawbi, Anne L Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2014
A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastomaYaping Shou, Douglas M Robinson, Dereck D Amakye, et al.
Pageof 1